News

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks
Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...
CNBCTV1822m
Alembic Pharma shares in focus as US drug regulator clears Panelav plant
Alembic Pharma received the final approval from the USFDA for its abbreviated new drug application (ANDA) for Carbamazepine ...
Health and Me on MSN30m
FDA Greenlights Zevaskyn for Rare Genetic Skin Condition
With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...